2020年9月17日 · B cell maturation antigen (BCMA) is a novel treatment target for multiple myeloma (MM) due to its highly selective expression in malignant plasma cells (PCs). Multiple BCMA-targeted therapeutics, including antibody-drug conjugates (ADC), chimeric antigen receptor (CAR)-T cells, and bispecific T cell …

3.1. Antibody-Drug Conjugates (ADC) The understanding of the MM plasma cells biology and its interaction within the bone marrow microenvironment build the foundation of further developments of therapeutic antigen targets in MM [30,31].ADCs are among the fastest growing agents in plasma cell malignancies [].Due to their mAbs, binding ADCs to specific antigen on tumor cells, a sparing of normal ...

2020年2月13日 · Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy. Front Immunol. 2018;9:1821. Article CAS PubMed PubMed Central Google Scholar

2025年1月2日 · A new BCMA-targeted multiple myeloma drug, P-BCMA-ALLO1, is being developed by Poseida Therapeutics. The company was granted an orphan drug designation by the FDA in March 2024 for the treatment of multiple myeloma in adults whose myeloma has relapsed or hasn’t responded to prior treatment. Early data from the first phase of clinical trials ...

Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy. Front Immunol. 2018;9:1821. doi: 10.3389/fimmu.2018.01821. [PMC free article] [Google Scholar] 59. Kinneer K, Meekin J, Tiberghien AC, Tai YT, Phipps S, Kiefer CM, et al. SLC46A3 as a potential predictive biomarker for antibody-drug ...

B cell maturation antigen (BCMA)-based immunotherapies with multiple mechanisms of action against MM cells. Various BCMA-based treatment modalities are under clinical development are listed in Table 1 and shown here. BCMA-NK Bi or Tri Ab, not shown here, can also specifically induce effector cell-mediated lysis of MM cells.

Despite considerable advances in the treatment of multiple myeloma (MM) in the last decade, a substantial proportion of patients do not respond to current therapies or have a short duration of response. ... B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches Leukemia. 2020 Apr;34(4 ...

2025年2月1日 · Chimeric antigen receptor (CAR) T cell therapy has emerged as a groundbreaking immunotherapy, demonstrating significant efficacy in treating B cell malignancies. In the context of multiple myeloma (MM), B cell maturation antigen (BCMA) has been identified as a critical target, driving the developmen …

2019年10月16日 · B cell maturation antigen (BCMA) is a novel treatment target for multiple myeloma (MM) due to its highly selective expression in malignant plasma cells (PCs). Multiple BCMA-targeted therapeutics, including antibody-drug conjugates (ADC), chimeric antigen receptor (CAR)-T cells, and bispecific T cell engagers (BiTE), have achieved remarkable clinical response in patients with relapsed and ...

BCMA. B-cell maturation antigen (BCMA), also known as TNFRSF17 or CD269, is a member of the tumor necrosis factor receptor family (8–10).Its expression is restricted to some B-cell lineage cells with fairly uniform expression on normal plasma cells and myeloma cells, making it an ideal target antigen (11–13).It is essential for the survival of …